Comparative analysis of two consecutive phase II studies with IFN-α and IFN-α + Ara-C in untreated chronic-phase CML patients

Bone Marrow Transplantation

Volumn 17, Issue SUPPL. 3, 1996, Pages

  Thaler, J ^a,b   Hilbe, W ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

CML; Interferon alpha; LD ara C

Indexed keywords

ALPHA INTERFERON; ALPHA2 INTERFERON; ANTILEUKEMIC AGENT; CYTARABINE; HYDROXYUREA;

ADOLESCENT; ADULT; AGED; BLOOD TOXICITY; CHILD; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; DRUG EFFICACY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; AUSTRIA; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; CYTARABINE; FEMALE; HUMANS; INTERFERON TYPE I, RECOMBINANT; LEUKEMIA, MYELOID, CHRONIC-PHASE; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 0029896424     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (18)

1. Tura S, Baccarani M, Zuffa E et al. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. New Engl J Med 1994; 330: 820-825.
2. Hehlmann R, Heimpel H, Hasford J et al. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood 1994; 84: 4064-4077.
3. Allan NC, Richards SM, Shepherd PCA on behalf of the UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukemia. UK Medical Research Council randomised, multicentre trial of interferon-αn1 for chronic mycloid leukaemia: improved survival irrespective of cytogenetic response. Lancet 1995; 345: 1392-1397.
4. Talpaz M, Kantarjian HM, McCredie KB, Trujillo J, Keating MJ, Gutterman JU. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha in chronic myelogenous leukemia. New Engl J Med 1986; 314: 1065-1069.
5. Kloke O, Niederle N, Qiu JY et al. Impact of Interferon alpha-induced cytogenetic improvement of survival in chronic myelogenous leukaemia. Br J Haematol 1993; 83: 399-403.
6. Ozer H, George SL, Schiffer CA et al. Prolonged subcutaneous administration of recombinant α2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B Study 8583. Blood 1993; 82: 2975-2984.
7. Thaler J, Gastl G, Fluckinger T et al. Treatment of chronic myelogenous leukemia with interferon alfa-2c: Response rate and toxicity in a phase II multicenter study. Sem Hematol 1993; 30 (Suppl. 3): 17-19.
8. Kantarjian HM, Smith TL, O'Brian S et al. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy. Ann Intern Med 1995; 122: 254-261.
9. Spiro TE, Mattelaer MA, Efira A and Stryckmans P. Sensitivity of myeloid progenitor cells in healthy subjects and patients with chronic myeloid leukemia to chemotherapeutic agents. J Natl Cancer Inst 1981; 66: 1053-1059.
10. Sokal JE, Leong SS and Gomez GA. Preferential inhibition by cytarabine of CFU-GM from patients with chronic granulocytic leukemia. Cancer 1987; 59: 197-202.
11. Guilhot F, Dreyfus B, Desmarest M-C et al. Combined therapy interferon and chemotherapy in chronic myelogenous leukemia. Nouv Rev Fr Hematol 1989; 31: 171-173.
12. Thaler J, Fluckinger T, Huber H et al. Treatment of 11 patients with chronic myelogenous leukemia with interferon-alpha-2c and low-dose cytosine arabinoside. Leuk Res 1993; 17: 711-715.
13. Thaler J, Gastl G, Fluckinger T et al. Interferon alpha-2c therapy of patients with chronic myelogenous leukemia: long term results of a multicenter phase-II study. Ann Hematol 1996; in press.
14. Thaler J, Hilbe W, Apfelbeck U et al. Interferon-alpha-2c and LD-ara-C for the treatment of patients with CML: preliminary results of the Austrian multicenter phase II study. 1995; submitted for publication.
15. Guilhot F, Abgrall J, Harousseau J et al. A multicenter randomised study of alpha 2b interferon, (IFN) and hydroxyurea (HU) with or without cytosine-arabinoside (ara-c) in previously untreated patients with Ph + chronic myelocytic leukemia (CML): preliminary results. Leuk Lymphoma 1993; 11 (Suppl. 1): 181-183.
16. Talpaz M, O'Brian S, Kurzrock R, Gutterman JU, Deisseroth A, Kantarjian HM. Alpha interferon (IFN-α) and chemotherapy combination in early chronic myelogenous leukemia (CML) - a summary of 3 M.D. Anderson studies. Proc Asco 1992; 11: 274 (Abstract).
17. Kantarjian HM, Keating MJ, Estey EH et al. Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-α and low-dose cytarabine. J Clin Oncol 1992; 10: 772-778.
18. Arthur CK and Ma DDF. Combined interferon alfa-2a and cytosine arabinoside as first-line treatment for chronic myeloid leukemia. Acta Haemat 1993; 89 (Suppl. 1): 15-21.